Psilocybin with talk therapy for severe irritable bowel syndrome
Tests psilocybin with guided therapy in adults with severe irritable bowel syndrome.
Key facts
- Who runs it
- NYU Langone Health
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 10 people, planned
- Started
- Aug 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Psilocybin 25 mg
- Psychotherapy Treatment Session
- Niacin 100 mg
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe irritable bowel syndrome (IBS) whose symptoms continue despite medicines. It tests psilocybin with psychotherapy against niacin with psychotherapy.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Severe IBS by Rome IV criteria: an IBS-SS score >300, or one or more emergency room visits for belly pain in the last year.
- Earlier treatment
- IBS symptoms must continue despite drug treatment. People taking antidepressants, antipsychotics, mood stabilizers, other serotonin-acting drugs or supplements, or niacin cannot join.
Main reasons for not taking part
- Unstable medical problems, such as heart failure, heart rhythm problems (QT interval > 450), recent stroke or serious liver or kidney problems
- Psychotic illness, bipolar disorder with psychotic features, major depression, or a close relative with psychotic illness
- Active alcohol or drug use disorder in the past year, or a positive urine drug test
- Serious suicidal thoughts or behaviour, or a memory and thinking score (MoCA) < 23
- Being pregnant or breastfeeding
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Severe IBS patients meeting Rome IV criteria. Severe IBS is defined by IBS-SS >300, or one or more emergency room (ER) visit for abdominal pain in the last year
- Experiencing persistent IBS symptoms despite pharmacologic therapy
- Have an identified support person
- Agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing
- Participants of childbearing potential must agree to practice an effective means of birth control throughout the duration of the study
- Participants must agree to send outside medical records in order for the study team to verify eligibility
Who cannot take part
- Concurrent Medications; Antidepressants; Centrally-acting serotonergic agents (e.g., monoamine oxidase inhibitors (MAOIs)); Antipsychotics (e.g., first and second generation); Mood stabilizers (e.g., lithium, valproic acid); Aldehyde dehydrogenase inhibitors (e.g., disulfiram); Significant inhibitors of UGT 1A0 or UGT 1A10; Niacin
- Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP)
- Have any psychological or physical symptom, medication or other relevant finding prior to randomization, based on the clinical judgment of the PI or relevant clinical study staff that would make a participant unsuitable for the study
- Significant central nervous system (CNS) pathology. Examples include:; Primary or secondary cerebral neoplasm; Epilepsy; History of stroke; Cerebral aneurysm; Dementia; Delirium
- Primary psychotic or affective psychotic disorders. Examples include current or past DSM-5 criteria for:; Schizophrenia spectrum disorders; Schizoaffective disorder; Bipolar I or II disorder with psychotic features; Major Depressive Disorder; Substance induced psychotic disorders; Paranoid personality disorder; Delusional disorder; Borderline personality disorder; Any other psychotic illness
- Family history of psychotic or serious bipolar spectrum illnesses. Examples include first-degree relative with:; Schizophrenia spectrum disorders; Schizoaffective disorder; Bipolar I disorder with psychotic features; Any other psychotic illness
- Active substance use disorders (SUDs) defined as Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year
- History of hallucinogen persisting perception disorder (HPPD)
- Cognitive impairment as defined by: Montreal Cognitive Assessment Test (MoCA) < 23
- Have a psychiatric condition judged to be incompatible with establishment of rapport with the study therapists or safe exposure to psilocybin
- Have an allergy or intolerance to either psilocybin on Niacin
- Unstable medical conditions or serious abnormalities on complete blood count, chemistries, or ECG that in the opinion of the study physician would preclude safe participation in the trial. Some examples include:; Congestive heart failure; Clinically significant arrhythmias (e.g.,; Ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., corrected QT interval > 450); Recent acute myocardial infarction or; Evidence of ischemia (in the last year); Malignant hypertension; Congenital long QT syndrome; History of valvular heart disease; Acute renal failure; Moderate to Severe hepatic impairment (Child Pugh class B and C); Respiratory failure; Recent stroke (< 1 year from signing of consent); Laboratory tests abnormalities (ALT ≥ 2X upper limit of normal (ULN), aspartate aminotransferase (AST) ≥ 2X ULN, Hemoglobin<11.5, platelets <150, White Blood Cells (WBC)>10, Sodium>150, Potassium K<3.5 or K>5.2); Abnormal and clinically significant results on the physical examination (BP>139/89 mmHG), heart rate (HR)>90bpm,; History of Pulmonary hypertension
- High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation. Examples include:; Agitation; Violent behavior
- Clinically significant suicidality or high risk of completed suicide defined as:; 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline; Any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts; Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior
- Pregnancy/lactation
- Subjects should not also be taking serotonin-acting dietary supplements (such as 5-hydroxy-tryptophan or St. John's wort)
- Be enrolled in another clinical trial assessing intervention(s) for anxiety, depression, and/or existential distress (e.g., pharmacologic or psychotherapeutic interventions)
- Are unable to provide external medical records or refuse to provide external medical records
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- NYU Langone HealthNew York, United StatesContact: Maysaa El ZoghbiNot yet recruiting
About the trial
What the trial wants to find out
This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session with single 25 mg oral "high" dose of psilocybin or a single 100 mg dose of niacin (active placebo) and attend 4 post-therapy integration sessions.
The 2 groups in the trial
- Intervention: PsilocybinTreatment being tested
Participants assigned to the intervention arm will receive psilocybin.
Treatment: Psilocybin 25 mg and Psychotherapy Treatment Session
- Control: Niacin (Placebo)Placebo, for comparison
Participants assigned to the control arm will receive a placebo (niacin).
Treatment: Psychotherapy Treatment Session and Niacin 100 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.
- Plain-language title
- Psilocybin with talk therapy for severe irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06760533, who can take part
- Record updated
- 5 March 2026